Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo.

The goal of this clinical trial is to learn if topical crisaborole ointment works to treat vitiligo. It will also learn about the safety of the drug. The main questions it aims to answer are:

Can the drug cause repigmentation of vitiligo lesions when used as topical form after microneedling? What medical problems do participants have when the drug used?

Participants will:

Visit the clinic once every 2 weeks to have the microneedling sessions for 3 months. and also they will have narrow band UVB sessions two times per week.

Record any side effect they have during or after the sessions.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Vitiligo Hypopigmentation Pigmentation Disorders Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients suffer from non-segmental stable vitiligo.
Patients who will accept to be included in the study and will sign a written consent.

Exclusion criteria

Patients with history of koebnerization or any sign of disease activity.
Patients with keloid tendency.
Patients with active infection.
Pregnant or lactating woman.

Treatment and study plan

microneedling with topical crisaborole

Procedure

From each patient 3 patches will be selected The first will have microneedling and topical crisaborole and NB UVB sessions The second will have microneedling and NB UVB sessions The third will be exposed only to NB UVB sessions The microneedling sessions will be every 2 weeks for 6 sessions

Primary outcomes

Repigmentation of vitiligo lesions

Time frame: 3 months from the start of treatment

The repigmentation responses will be expressed qualitatively as the following No change (0%-25%) = mild improvement (26%-50%) = moderate improvement (51%-75%) = good improvement (76%-100%) = excellent improvement

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. A Prospective Controlled Trial.

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jul 28, 2025
Registry last updated: Jul 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting